價(jià)格 | ¥428 | ¥622 | ¥913 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-09-29 |
中文名稱:SIS3 鹽酸鹽 | 英文名稱:(E)-SIS3 |
CAS:521984-48-5 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 98.83% | 產(chǎn)品類別: 抑制劑 |
貨號: T3636 |
名稱 | (E)-SIS3 |
描述 | (E)-SIS3 (SIS3), a selective Smad3 inhibitor, can attenuate TGF-β1-dependent Smad3 phosphorylation and DNA binding. It has no effect on p38 MAPK, Smad2, ERK or PI3K signaling. It also inhibits TGF-β1-induced myofibroblast differentiation of dermal fibroblasts and inhibits TGF-β2-induced endothelial cell differentiation in iPSCs. |
細(xì)胞實(shí)驗(yàn) | Normal human dermal fibroblasts are plated at a density of 105 cells/well in six-well culture plates and grown until subconfluence in MEM containing 10% FCS. Cells are quiesced by 24-h incubation in serum-free MEM, followed by incubation in serum-free medium in the presence or absence of SIS3 before the collection of cells for 72 h. Then, the cells are detached from the wells by trypsin treatment and counted using a Coulter counter.(Only for Reference) |
體外活性 | Addition of SIS3 attenuates the effects of TGF-β1 by reducing the transcriptional activity. SIS3 also inhibits the myofibroblast differentiation of fibroblasts by TGF-β1. SIS3 completely diminishes the constitutive phosphorylation of Smad3 as well as the up-regulated type I collagen expression in scleroderma fibroblasts, thus abolishes the ECM overexpression in the TGF-β1-treated normal dermal fibroblasts and scleroderma fibroblasts in vitro[1]. |
體內(nèi)活性 | SIS3 inhibits Smad3 activation in streptozotocin(STZ)-induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice. It also reduces AGE-induced EndoMT and decreases EndoMT in STZ-induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice. SIS3 significantly reduces collagen IV and fibronectin expression in the glomeruli and tubulointerstitium of STZ-injected Tie2-Cre;Loxp-EGFP mice, suggesting that SIS3 retards the early development of STZ-induced diabetic glomerulosclerosis and tubulointerstitial fibrosis. However, SIS3 administration does not reduce proteinuria[2]. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | Ethanol : 23 mg/mL (46.9 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 90 mg/mL (183.7 mM) |
關(guān)鍵字 | myofibroblast | inhibit | TGF-β1 | SIS 3 | TGF-beta/Smad | (E)SIS3 | Smad3 | (E)-SIS3 | Transforming growth factor beta | fibroblasts | differentiation | (E) SIS3 | phosphorylation | (E)-SIS-3 | SIS-3 | Inhibitor |
相關(guān)產(chǎn)品 | Monocrotaline | Pirfenidone | RepSox | A 83-01 | Chromenone 1 | LY-364947 | BMP signaling agonist sb4 | SB-431542 | Galunisertib | Alantolactone |
相關(guān)庫 | 抑制劑庫 | 抗乳腺癌化合物庫 | 經(jīng)典已知活性庫 | 抗癌化合物庫 | 已知活性化合物庫 | 細(xì)胞因子抑制劑庫 | 抗結(jié)直腸癌化合物庫 | 高選擇性抑制劑庫 | TGF-β/Smad靶點(diǎn)化合物庫 | 細(xì)胞重編程化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP4年
|
四川省維克奇生物科技有限公司
|
2024-11-15 | |
詢價(jià) |
VIP5年
|
上海澤葉生物科技有限公司
|
2024-11-15 | |
詢價(jià) |
VIP1年
|
寶雞締都醫(yī)藥化工有限公司
|
2024-10-15 | |
¥1680 |
VIP13年
|
湖南匯百侍生物科技有限公司
|
2024-10-11 | |
¥431.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-08-16 | |
¥4474.34 |
VIP10年
|
西格瑪奧德里奇(上海)貿(mào)易有限公司
|
2023-10-27 |